Mizoribine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizoribine
Accession Number
DB12617
Description

Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 259.216
Monoisotopic: 259.080435163
Chemical Formula
C9H13N3O6
Synonyms
  • BREDININ
  • Mizoribine

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Mizoribine.
AcetophenazineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Acetophenazine.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Mizoribine.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Mizoribine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mizoribine.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Mizoribine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mizoribine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Alimemazine.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Mizoribine.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Mizoribine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Imidazole ribonucleosides and ribonucleotides
Sub Class
1-ribosyl-imidazolecarboxamides
Direct Parent
1-ribosyl-imidazolecarboxamides
Alternative Parents
Glycosylamines / Pentoses / 2-heteroaryl carboxamides / Carbonylimidazoles / N-substituted imidazoles / Vinylogous amides / Vinylogous acids / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 8 more
Substituents
1-ribosyl-imidazolecarboxamide / 2-heteroaryl carboxamide / Alcohol / Aromatic heteromonocyclic compound / Azacycle / Azole / Carboxamide group / Carboxylic acid derivative / Glycosyl compound / Heteroaromatic compound
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
4JR41A10VP
CAS number
50924-49-7
InChI Key
HZQDCMWJEBCWBR-UUOKFMHZSA-N
InChI
InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide
SMILES
NC(=O)C1=C(O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

References

General References
Not Available
Human Metabolome Database
HMDB0041934
PubChem Compound
104762
PubChem Substance
347828830
ChemSpider
94571
BindingDB
68669
ChEBI
31858
ChEMBL
CHEMBL245019
ZINC
ZINC000003812887
PDBe Ligand
MZR
Wikipedia
Mizoribine
PDB Entries
3b1n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentNephritis, Lupus1
3CompletedTreatmentNephrotic Syndrome1
3CompletedTreatmentRheumatoid Arthritis1
2Unknown StatusTreatmentRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility36.1 mg/mLALOGPS
logP-2.3ALOGPS
logP-2ChemAxon
logS-0.86ALOGPS
pKa (Strongest Acidic)8.19ChemAxon
pKa (Strongest Basic)2.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.55 m3·mol-1ChemAxon
Polarizability23.58 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 23:14 / Updated on February 21, 2021 18:53